The global huntington’s disease treatment market size is expected to be worth around US$ 1.7 billion by 2030, according to a new report by Vision Research Reports.
The global huntington’s disease treatment market size is expected to be worth around US$ 1.7 billion by 2030, according to a new report by Vision Research Reports.
The global huntington’s disease treatment market size was valued at US$ 360.0 million in 2020 and is anticipated to grow at a CAGR of 19.5% during forecast period 2021 to 2030.
Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/37478
Growth Factors
The market is largely driven by factors such as rapid uptake of disease-modifying therapies, increased adoption of novel therapeutics, and increase in R&D activities.
Huntington’s disease is an inherited neurodegenerative disorder characterized by a combination of motor, cognitive, and psychiatric symptoms. Currently, only two symptom-alleviating therapies are specifically approved for this disorder: Xenazine and Austedo. Off-label medications are used extensively due to lack of approved alternatives.
The pipeline for Huntington’s disease is expected to witness rapid developments in the coming years as disease-modifying drugs transform the market landscape. Improved disease understanding has led to significant progress in the development of therapeutic approaches aimed at modifying specific changes linked to the causative mutation. The potential role of RNA antisense technology and stem cell therapy are under active clinical investigation. Wave Life Sciences and Ionis Pharma’s antisense oligonucleotides aim to target underlying disease cause and are expected to contribute significantly to market growth.
Report Coverage
| Report Scope | Details |
| Market Size | US$ 1.7 billion by 2030 |
| Growth Rate | CAGR of 19.5% From 2022 to 2030 |
| Largest Market | North America |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Treatment |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Mentioned | H. Lundbeck A/S; Teva Pharmaceutical Industries Ltd.; Bausch Health Companies Inc.; Hetero; Lupin; Hikma Pharmaceuticals PLC; Dr. Reddy’s Laboratories Ltd.; Sun Pharmaceutical Industries Ltd. |
Report Highlights
Huntington’s disease can be caused by dopamine imbalance, which contributes both to involuntary movements such as chorea as well as decelerating voluntary movements. Due to lack of approved medications, the current clinical needs of HD are largely served by off-label use of conventional antipsychotics and anti-epileptics prescribed for treatment of severe emotional as well as motor impairment characteristics.
The Huntington’s disease treatment market is expected to witness novel product launches, including approval of several disease-modifying therapies. Current research in HD focuses on using novel treatments such as immuno-modulating therapies, gene therapy (using antisense oligonucleotides, micro RNAs (miRNA), mRNA splicing, and zinc-finger DNA binding protein (ZFP)).
Nucleotide-based gene silencing therapies such as RNAi and antisense oligonucleotides offer promising treatment options. IONIS-HTTRx is the first drug to demonstrate significant, dose-dependent reductions of mutant Huntingtin (mHTT) protein in HD patients. Wave Life Sciences’ allele-specific drugs have the potential to target more than half of the HD patient population. Both drugs are expected to contribute significantly to market growth.
High unmet needs within the market present a key commercial opportunity to develop breakthrough disease-modifying therapies. The Huntington’s disease pipeline is expected to witness new developments over the next decade as several privately-held and innovation-driven pharmaceutical companies venture into the HD treatment arena. The introduction of disease-modifying drugs is poised to transform the market landscape. With ongoing research aiding in further understanding its pathogenesis, there are increasingly significant opportunities for drug companies to develop new drugs with novel mechanisms of action.
Lowering levels of mHTT has been demonstrated to be therapeutically beneficial for HD. At present, more than 20 products are being studied for treatment for Huntington’s disease in various stages of clinical investigation. Wave’s PRECISION-HD program is the first to follow an allele-specific approach, which is aimed at targeting the underlying cause of Huntington’s disease.
Stem cell therapy is also generating interest as a potential treatment for the condition. Currently, Cellavita, in collaboration with Azidus Pharma, is investigating cell therapy CELLAVITA-HD in Phase I ADORE-DH trial.
U.S. dominated the market with more than 60.0% share in 2016 and is projected to maintain the leading position through 2023. Multiple product launches during the forecast period, increased adoption of novel therapeutics, and presence of key manufacturers in the country are a few factors responsible for its dominance.
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/37478
Growth Drivers
Growing Adoption of Improved Medications and Therapies to Drive the Demand for Effective Treatments
The involvement of major market players in researching for a cure for Huntington’s disease (HD) is a significant factor estimated to result in the market growth. This can be attributed to the rising patient population and prevalence of disease globally, mainly in the North America and Europe region. The requirement for disease-modifying drugs and other treatment methods for HD that is not yet fulfilled is predicted to further impact the market growth positively.
Growing Research and Development Activities to Raise the Market Growth
Since there is no proper treatment or medication for Huntington’s disease, there is a huge scope of research and development of its treatment methods. This is anticipated to significantly raise the market growth over the forecast period. Moreover, the promising government initiatives that promote the development of new drugs is estimated to be another factor supporting the market growth.
Restraints
Limited Availability of Drugs to Hamper the Market Growth
The number of approved drugs for Huntington’s disease are limited as a result of strict policies and regulations. This is anticipated to hinder the market growth over the forecast period. Furthermore, the lack of awareness about this disorder in major parts of the world is predicted to restrict the growth of Huntington’s disease treatment market.
Key Market Trends
The Symptomatic Treatment Segment is Expected to Hold a Major Market Share in the Huntington’s Disease Treatment Market
The symptomatic treatment segment is expected to account for the major share during the forecast period. Relatively high availability and usage rate of symptom management therapeutics have bolstered the segment revenue. Need for multiple treatments and the intervention of a multispecialty care team for symptomatic management results in additional expense, thereby high revenue generation through this segment.
Symptomatic therapeutic development majorly focuses on motor impairment and chorea. Chorea remains the most prominent clinical feature of Huntington’s disease for which most of the therapeutic studies have been carried out. For instance, in December 2021, Neurocrine Biosciences announced valbenazine has significantly lessened chorea in people with Huntington’s disease in Phase 3 clinical trial titled-KINECT-HD. Furthermore, a research paper was published in May 2021 in the journal Brain that demonstrates that the use of gene editing therapy in the early stages of Disease exhibits the potential to slow down symptom progression. These ongoing studies are anticipated to play a crucial role in defining the market share of this segment in the coming years.
Key Players
Valeant Pharmaceuticals, Teva Pharmaceuticals, Wave Life Sciences, Ionis Pharmaceuticals/ Roche, Raptor Pharmaceuticals, and Prana Biotechnology
Market Segmentation
- Treatment Outlook
- Symptomatic Therapy
- Disease-Modifying Therapy
- Regional Outlook
- U.S.
- U.K.
- France
- Germany
- Italy
- Spain
- Japan
Click Here to View Full Report Table of Contents
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/37478
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333